Immunotherapy

MHRA approves UK’s first immunotherapy for type 1 diabetes

Teplizumab (Tzield; Sanofi) has been approved by the MHRA for delaying the progression of type 1 diabetes mellitus.…

Case-based learning: complex decision making when using advanced therapy investigational medicinal products

Advanced therapy investigational medicinal products (ATIMPs) are increasingly the subject of clinical trials. What happens when an ATIMP is necessary for a patient but does not fit the study specifications?…

SARS-CoV2 antivirals are essential, but they are not silver bullets

The UK government's 'living with COVID-19' policy is relying too much on antiviral treatments, but now is not the time to relax.…

Collaborate to deliver biggest ever flu vaccination programme, RPS and RCGP say

Pharmacists and GPs should work together to make sure as many people as possible get their flu vaccination this winter, the Royal Pharmaceutical Society and the Royal College of General Practitioners have said.…

Going against type: the new class of cancer therapies targeting mutations rather than tissues

‘Tumour agnostic’ drugs offer a more effective and tolerable therapy for a wide range of people with cancer, so why has the NHS rejected its first one?…

Combination immunotherapy for melanoma improves long-term survival rates

Patients with advanced melanoma treated with a combination of ipilimumab and nivolumab are more likely to be alive five years later than patients treated with ipilimumab alone or nivolumab alone.…

First patient in Wales to begin CAR-T personalised therapy

A patient in Wales will become the first in the country to start chimeric antigen receptor T-cell therapy after other treatments for his lymphoma were unsuccessful.…

Immunotherapy delays type 1 diabetes mellitus in high-risk individuals

Certain individuals at high risk of developing type 1 diabetes mellitis can delay progression to clinical disease by two years or more with a two-week course of teplizumab, according to results of a phase II study.…

First-line immunotherapy does not improve survival in metastatic lung cancer

Single or combination first-line immunotherapy does not significantly extend survival compared with chemotherapy in metastatic non small-cell lung carcinoma, trial results have shown.…